CL2022003643A1 - Compuestos macrocíclicos y métodos de uso de los mismos. - Google Patents

Compuestos macrocíclicos y métodos de uso de los mismos.

Info

Publication number
CL2022003643A1
CL2022003643A1 CL2022003643A CL2022003643A CL2022003643A1 CL 2022003643 A1 CL2022003643 A1 CL 2022003643A1 CL 2022003643 A CL2022003643 A CL 2022003643A CL 2022003643 A CL2022003643 A CL 2022003643A CL 2022003643 A1 CL2022003643 A1 CL 2022003643A1
Authority
CL
Chile
Prior art keywords
macrocyclic
methods
binding motif
macrocyclic compounds
eulbm
Prior art date
Application number
CL2022003643A
Other languages
English (en)
Inventor
Jakob Fuhrmann
Wayne Fairbrother
Hao Wu
Jeremy Murray
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2022003643A1 publication Critical patent/CL2022003643A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proveen compuestos macrocíclicos que comprenden un motivo de unión a la ubiquitina ligasa E3 (EULBM) y al menos un aminoácido, y métodos para preparar y usar tales EULBM macrocíclicos para el tratamiento del cáncer o de una condición fibrótica. También se proveen inductores químicos heterobifuncionales macrocíclicos de degradación (CIDE) que comprenden un motivo de unión a la ubiquitina ligasa E3 (EULBM) y un motivo de unión a la proteína diana (TPBM) unidos por al menos un aminoácido.
CL2022003643A 2020-06-23 2022-12-19 Compuestos macrocíclicos y métodos de uso de los mismos. CL2022003643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063043071P 2020-06-23 2020-06-23

Publications (1)

Publication Number Publication Date
CL2022003643A1 true CL2022003643A1 (es) 2023-05-26

Family

ID=77207221

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2022003643A CL2022003643A1 (es) 2020-06-23 2022-12-19 Compuestos macrocíclicos y métodos de uso de los mismos.
CL2023002555A CL2023002555A1 (es) 2020-06-23 2023-08-29 Compuestos macrocíclicos y métodos de uso de los mismos (divisional ).
CL2025000750A CL2025000750A1 (es) 2020-06-23 2025-03-13 Compuestos macrocíclicos y métodos de uso de los mismos.
CL2025000748A CL2025000748A1 (es) 2020-06-23 2025-03-13 Compuestos macrocíclicos y métodos de uso de los mismos.

Family Applications After (3)

Application Number Title Priority Date Filing Date
CL2023002555A CL2023002555A1 (es) 2020-06-23 2023-08-29 Compuestos macrocíclicos y métodos de uso de los mismos (divisional ).
CL2025000750A CL2025000750A1 (es) 2020-06-23 2025-03-13 Compuestos macrocíclicos y métodos de uso de los mismos.
CL2025000748A CL2025000748A1 (es) 2020-06-23 2025-03-13 Compuestos macrocíclicos y métodos de uso de los mismos.

Country Status (17)

Country Link
US (2) US12187816B2 (es)
EP (1) EP4168121A2 (es)
JP (1) JP2023532233A (es)
KR (1) KR20230026461A (es)
CN (1) CN115702026A (es)
AR (1) AR122707A1 (es)
AU (1) AU2021297799A1 (es)
BR (1) BR112022026364A2 (es)
CA (1) CA3185149A1 (es)
CL (4) CL2022003643A1 (es)
CO (1) CO2022018532A2 (es)
CR (1) CR20220658A (es)
IL (1) IL299163A (es)
MX (1) MX2022016454A (es)
PE (1) PE20230617A1 (es)
TW (1) TWI906316B (es)
WO (1) WO2021262731A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260001914A1 (en) * 2022-07-21 2026-01-01 Merck Sharp & Dohme Llc Macrocyclic peptides targeting kras
ES3041442T3 (en) * 2022-12-27 2025-11-12 Evonik Oxeno Gmbh & Co Kg Process for the preparation of a phosphoramidite and its further conversion to monophosphite
KR20260028831A (ko) * 2023-06-26 2026-03-04 알부넥스트 엘엘씨 Glp-1/gip/글루카곤 수용체를 활성화시키는 알부민 결합 거대분자 삼중효능제 및 이를 위한 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144233A (en) 1977-02-16 1979-03-13 The Dow Chemical Company Method for preparing benzo-(1,3,4)-benzotriazepines
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
ES2233070T3 (es) * 1998-08-20 2005-06-01 ELI LILLY & COMPANY Sintesis de analogos peptidicos ciclicos modificados en el anillo.
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
EP3050885B1 (en) 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
AU2010314395B2 (en) 2009-11-05 2015-04-09 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN103119160B (zh) 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
JP6532599B2 (ja) 2015-09-02 2019-06-19 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
EP3675878A4 (en) * 2017-10-02 2021-06-16 Fred Hutchinson Cancer Research Center LUTEINIZING HORMONE RECEPTOR BINDERS AND LUTEINIZING HORMONAGONISTS FOR IDENTIFICATION, EXPANSION, ABLATION AND MODIFICATION OF PRIMITIVE STEM CELL POPULATIONS
EP3724216A1 (en) 2017-12-15 2020-10-21 Dana Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
WO2019162974A1 (en) * 2018-02-23 2019-08-29 Ulisse Biomed S.R.L. Method to diagnose cancer progression based on prokaryotic biomarkers and molecules for use in the treatment of cancer progression

Also Published As

Publication number Publication date
TW202219056A (zh) 2022-05-16
CL2025000750A1 (es) 2025-07-04
MX2022016454A (es) 2023-03-06
CO2022018532A2 (es) 2022-12-30
IL299163A (en) 2023-02-01
US12187816B2 (en) 2025-01-07
AU2021297799A1 (en) 2022-12-22
WO2021262731A3 (en) 2022-02-24
CL2023002555A1 (es) 2024-01-26
AR122707A1 (es) 2022-09-28
CN115702026A (zh) 2023-02-14
JP2023532233A (ja) 2023-07-27
KR20230026461A (ko) 2023-02-24
EP4168121A2 (en) 2023-04-26
CA3185149A1 (en) 2021-12-30
BR112022026364A2 (pt) 2023-01-17
US20250129125A1 (en) 2025-04-24
WO2021262731A2 (en) 2021-12-30
CL2025000748A1 (es) 2025-07-04
US20220106361A1 (en) 2022-04-07
TWI906316B (zh) 2025-12-01
CR20220658A (es) 2023-04-26
PE20230617A1 (es) 2023-04-14

Similar Documents

Publication Publication Date Title
CL2022003643A1 (es) Compuestos macrocíclicos y métodos de uso de los mismos.
BR112021017583A2 (pt) Compostos, composições e métodos para o tratamento de doença
MX2024014691A (es) Enlazadores de conjugacion mejorados
JOP20210337A1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
CO2021009695A2 (es) Conjugados de il-2 y métodos de uso de este
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2021007152A (es) Inhibidores de apol1 y sus metodos de uso.
ECSP20021323A (es) Proteínas de unión condicionalmente activadas restringidas
CO2021016504A2 (es) Inhibidores de cdk
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
ECSP10010413A (es) Inhibidores macrociclicos de serina proteasa
MX2024002261A (es) Molecula de union de fap/cd40 y uso medicinal de la misma.
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
MX2024002411A (es) Antagonista biológico que contiene anillos aromáticos, y método para su preparación y su uso.
AR112101A1 (es) Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll).
BR112022012278A2 (pt) Combinações
MX2022007623A (es) Combinaciones.
CO2021012375A2 (es) Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo
WO2024077023A3 (en) Cereblon-recruiting bcl-xl/bcl-2 dual degraders
DOP2024000085A (es) Compuestos dirigidos a pmp22 para el tratamiento de la enfermedad de charcot-marie-tooth
MX2022003778A (es) Tratamiento de la hepatitis alcoholica.
AR128704A1 (es) Procedimiento para preparar 4-metil-2-propan-2-il-piridin-3-carbonitrilo
BR112022021918A2 (pt) Composições e métodos para o tratamento de fibrose cística
CO2022008127A2 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
CO2023011625A2 (es) Uso de luvadaxistat para el tratamiento de deterioro cognitivo